Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

D-916

Supelco

N-Desmethylclomipramine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C18H21ClN2 · HCl
Numéro CAS:
29854-14-6
Poids moléculaire :
337.29
Numéro CE :
200-659-6
Numéro MDL:
MFCD00792880
Code UNSPSC :
41116107
ID de substance PubChem :
329798895
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol (as free base)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

ClC1=CC2=C(C=C1)CCC3=C(C=CC=C3)N2CCCNC.[H]Cl

InChI

1S/C18H21ClN2.ClH/c1-20-11-4-12-21-17-6-3-2-5-14(17)7-8-15-9-10-16(19)13-18(15)21;/h2-3,5-6,9-10,13,20H,4,7-8,11-12H2,1H3;1H

Clé InChI

KMDDAZOLOSKTKZ-UHFFFAOYSA-N

Catégories apparentées

Description générale

N-Desmethylclomipramine is a primary plasma metabolite of the tricyclic antidepressant clomipramine. Clomipramine is a tricyclic antidepressant used to treat many conditions from major depression and panic disorder to narcolepsy and obsessive compulsion disorder (OCD). This Certified Snap-N-Spike® Solution is applicable for use in urine drug testing, clinical toxicology, or forensic analysis by LC-MS/MS or GC/MS.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

O Dale et al.
Veterinary and human toxicology, 36(4), 309-310 (1994-08-01)
A 27-y-old male was admitted deeply comatosed 5-6 h after taking approximately 15 g clomipramine. The prominent feature of the case was a biphasic course of clomipramine and desmethylclomipramine serum concentrations, possibly caused by delayed drug absorption. Clinically, 2 serious
Plasma concentrations after a clomipramine intoxication.
L M Stolk et al.
Journal of analytical toxicology, 22(7), 612-613 (1998-12-10)
Mario Rossi et al.
Journal of cell science, 122(Pt 18), 3330-3339 (2009-08-27)
Alterations in the autophagic pathway are associated with the onset and progression of various diseases. However, despite the therapeutic potential for pharmacological modulators of autophagic flux, few such compounds have been characterised. Here we show that clomipramine, an FDA-approved drug
K Shimoda et al.
Journal of clinical psychopharmacology, 19(5), 393-400 (1999-10-03)
The aim of this study was to compare the disposition of the tricyclic antidepressant clomipramine (C) in Japanese and Swedish patients receiving continuous treatment. Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving
Clinical pharmacology and therapeutics, 66(2), 152-165 (1999-08-25)
To examine the problems of establishing dose-effect and concentration-effect relationships of antidepressant therapy with clomipramine. This randomized double-blind study compared five fixed doses of clomipramine hydrochloride: 25, 50, 75, 125, and 200 mg/day in hospitalized or day patients at nine
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique